Patents Examined by Kamal Saeed
  • Patent number: 11911372
    Abstract: A compound of formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: February 27, 2024
    Assignee: CTXT PTY LTD
    Inventors: Paul Anthony Stupple, Helen Rachel Lagiakos, Richard Charles Foitzik, Michelle Ang Camerino, George Nikolakopoulos, Ylva Elisabet Bergman Bozikis, Wilhelmus Johannes Antonius Kersten, Scott Raymond Walker, Jonathan Grant Hubert
  • Patent number: 11903953
    Abstract: Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.
    Type: Grant
    Filed: March 30, 2023
    Date of Patent: February 20, 2024
    Assignee: Gilead Sciences, Inc.
    Inventor: Tomas Cihlar
  • Patent number: 11905275
    Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
    Type: Grant
    Filed: January 24, 2023
    Date of Patent: February 20, 2024
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Jincong Zhuo, Ding-Quan Qian, Song Mei, Ganfeng Cao, Yongchun Pan, Qun Li, Zhongjiang Jia
  • Patent number: 11905243
    Abstract: The present invention relates to compounds showing pharmacological activity towards the subunit ?2?#of voltage-gated calcium channels (VGCC), especially the ?2?-1 subunit of voltage-gated calcium channels. More particularly, the invention relates to alkylaminoproline derivatives having this pharmacological activity, to processes of preparation of such compounds, to pharmaceutical compositions comprising them, and to their use in therapy, in particular for the treatment of pain and/or as neuroprotective agents.
    Type: Grant
    Filed: October 28, 2022
    Date of Patent: February 20, 2024
    Assignee: ACONDICIONAMIENTO TARRASENSE
    Inventors: Anita Wegert, Carmen Almansa-Rosales
  • Patent number: 11905258
    Abstract: The present disclosure is concerned with 2-aminoaryl-5-aryloxazole compounds that are capable of activating NF-?B signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD), and neuromuscular disorders such as, for example, Duchenne muscular dystrophy (DMD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: February 20, 2024
    Assignee: Southern Research Institute
    Inventors: Mark J. Suto, Bini Mathew, Rita Cowell, Corinne E. Augelli-Szafran
  • Patent number: 11897875
    Abstract: The present invention relates to novel alpha5 subunit-selective negative allosteric modulators of GABAA receptors that have been deuterated to improve their medicinal properties by prolonging their half-lives, rendering them useful as fast-acting pharmaceutical treatments for depression related disorders.
    Type: Grant
    Filed: August 9, 2022
    Date of Patent: February 13, 2024
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Scott Thompson, Adam Van Dyke, Craig Thomas, Patrick Morris
  • Patent number: 11896584
    Abstract: The present invention is a method of treating or preventing Mycobacterium tuberculosis infection in a subject by administering to the subject an effective amount of oxazolidinone, specifically (N—(((S)-3-(dibenzo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
    Type: Grant
    Filed: December 1, 2022
    Date of Patent: February 13, 2024
    Assignees: THE JOHNS HOPKINS UNIVERSTY, UNIVERSITY OF ST. THOMAS
    Inventors: Gyanu Lamichhane, J. Thomas Ippoliti
  • Patent number: 11890260
    Abstract: The present disclosure generally relates to compositions comprising unique combinations of cannabinoids, antioxidants, and cofactors. The present disclosure also provides methods of making the compositions and methods for using the compositions for the treatment of mitochondrial ATP deficit disorders.
    Type: Grant
    Filed: July 26, 2021
    Date of Patent: February 6, 2024
    Assignee: Ilera Derm LLC
    Inventors: Brian Warrington, Karyn Grossman, Oludare Odumosu, Zoltan Kerekes
  • Patent number: 11884623
    Abstract: A process for the preparation of (R)-4-propyl-pyrrolidine-2-one, is provided which includes enzymatic conversion of dimethyl 3-propyl pentanedioate selectively into (S)-3-(2-methoxy-2-oxoethyl) hexanoic acid using Novozyme's Promea® enzyme, amidation of (S)-3-(2-methoxy-2-oxoethyl) hexanoic acid, followed by ester hydrolysis to obtain (S)-3-(2-amino-2-oxoethyl) hexanoic acid having high chiral purity >99% and converting the amide to amine by Hofmann rearrangement and cyclization resulting in (R)-4-propyl-pyrrolidine-2-one. It is further converted to Brivaracetam by N-alkylation with 2-bromobutyric acid, esterification followed by enzymatic resolution.
    Type: Grant
    Filed: July 5, 2022
    Date of Patent: January 30, 2024
    Assignee: DIVI'S LABORATORIES LTD.
    Inventors: Murali Krishna Prasad Divi, Nageswara Rao Bolneni, Leela Maheswara Rao Bandarupalli
  • Patent number: 11884637
    Abstract: A compound 3-(4-chlorophenyl)-5-{[5-methyl-2-(propan-2-yl)phenoxy]methyl}-1,2,4-oxadiazole compound, its synthesis, and its use as an anticancer and/or antimicrobial agent.
    Type: Grant
    Filed: August 28, 2023
    Date of Patent: January 30, 2024
    Assignee: KING FAISAL UNIVERSITY
    Inventors: Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Antar Ahmed Abdelhamid Ahmed, Amer A. Amer, Sahar M. Mohamed, Mohammad Mahboob Alam
  • Patent number: 11883380
    Abstract: Provided herein are compositions and methods for administration of sulcardine to a subject in need thereof.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: January 30, 2024
    Assignee: HUYABIO INTERNATIONAL, LLC
    Inventors: Suzanne J. Romano, Gary T. Elliott
  • Patent number: 11883384
    Abstract: In one aspect, the disclosure relates to compositions and methods for dispersing exiting Salmonella biofilms and inhibiting formation of Salmonella biofilms. In various aspects, the disclosed compositions can be used in methods of treating a persistent Salmonella infection, including an asymptomatic infection. Such infections can colonize a variety of tissues, including the gall-bladder. Also disclosed are methods of treating typhoid fever. Also disclosed are methods for mitigating or preventing secondary outbreaks of typhoid fever by treating asymptomatic subjects who had been symptomatic for typhoid fever at a previous time. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
    Type: Grant
    Filed: June 16, 2022
    Date of Patent: January 30, 2024
    Assignees: Ohio State Innovation Foundation, North Carolina State University
    Inventors: John Gunn, Laura Kuo, Christian Melander, William M. Huggins
  • Patent number: 11878003
    Abstract: This application relates to a composition for preventing, treating, and improving skeletal muscle atrophy, the composition including an organoselenium compound. The composition recovered the thickness of muscle fiber reduced by dexamethasone treatment. In addition, the treatment of mice in a muscle loss model showed that the composition had an effect of reducing damaged muscle and of restoring muscle mass. Therefore, it is expected that the composition can be effectively used for the treatment, prevention, or improvement of muscle atrophy.
    Type: Grant
    Filed: September 24, 2021
    Date of Patent: January 23, 2024
    Assignee: GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Darren Reece Williams, Da-Woon Jung, Ji-Hyung Lee, Hyun-Jun Kim, Seon-Wook Kim
  • Patent number: 11866409
    Abstract: Provided are ARTS mimetic compounds that act as novel antagonists for XIAP and Bcl-2. Further, the novel ARTS mimetic compounds of the presently claimed subject matter induce apoptosis and/or differentiation in premalignant and malignant cells and thereby restore their normal-like phenotype. Further provided are compositions, methods and uses of said ARTS mimetic compounds in the treatment of cancer and premalignant conditions.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: January 9, 2024
    Assignee: CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD.
    Inventors: Sarit Larisch, Dalit Barkan
  • Patent number: 11866421
    Abstract: Pyrimidine and Pyridine containing compounds are described herein that are enzyme p70S6K inhibitors useful in the treatment of S6K-dependent or S6K-mediated diseases and conditions, including but not limited to cancer, fibrotic metabolic and certain neurological disorders.
    Type: Grant
    Filed: May 31, 2021
    Date of Patent: January 9, 2024
    Assignee: Epigen Biosciences, INC.
    Inventors: Graham Beaton, Fabio Tucci, Satheesh Ravula, Suk Joong Lee, Chandravadan Shah
  • Patent number: 11857534
    Abstract: Methods are disclosed for treating neurodegenerative disorders, such as ALS and FTD by using an effective amount of a type I protein arginine methyltransferase (Type I PRMT) inhibitor to decrease cellular toxicity caused by dipeptide repeat proteins (DRPs).
    Type: Grant
    Filed: January 26, 2022
    Date of Patent: January 2, 2024
    Assignee: ALS Therapy Development Institute
    Inventors: Fernando G. Vieira, Alan Premasiri, Anna Gill
  • Patent number: 11858905
    Abstract: The present disclosure provides a plurality of the compounds. The compounds are capable of inhibiting Cathepsin L (CatL). A composition including at least one of these compounds is also provided. A method for treating or preventing one or more CatL-related diseases in a subject is further provided. The method may include administering the composition to the subject.
    Type: Grant
    Filed: March 31, 2023
    Date of Patent: January 2, 2024
    Assignees: BIOFRONT THERAPEUTICS (BEIJING) CO., LTD., RK PHARMTECH (BEIJING) LTD.
    Inventors: Lichao Fang, Yayi Wang, Tianwei Ma, Ling Song, Zheng Huang, Jin-Kui Yang, Shuo Gu
  • Patent number: 11851443
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R6, a, b, and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: January 19, 2022
    Date of Patent: December 26, 2023
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Roland Gendron, Melissa Fleury, Adam D. Hughes
  • Patent number: 11845726
    Abstract: Disclosed are novel C4-carbonothioate-substituted tryptamine derivative compounds and pharmaceutical and recreational drug formulations containing the same. The pharmaceutical formulations may be used to treat brain neurological disorders.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: December 19, 2023
    Assignee: ENVERIC BIOSCIENCES CANADA INC.
    Inventors: Jillian M. Hagel, Kaveh Matinkhoo, Peter J. Facchini
  • Patent number: 11845708
    Abstract: The present disclosure provides a method for photocleavage of an amide bond, the method has mild reaction conditions and can realize the cleavage of amide bonds by using light. The method comprises the following steps: subjecting 2,4-dinitrofluorobenzene to a reaction with an amino group of a substance represented by structural formula I with an ?-amino acid at the end to produce a compound 1 represented by structural formula II; then under light irradiation, subjecting the compound 1 to a cleavage reaction of amide bond; Wherein, R1 is the side chain group of ?-amino acid; R2 is: aryl, aliphatic hydrocarbon, —CH(R)—COOH or polypeptide.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: December 19, 2023
    Assignee: NANJING TECH UNIVERSITY
    Inventors: Xiaoqiang Chen, Tingwen Wei, Jing Wang, Yanyan Wang